Printer Friendly

IMRE: MORE TTP/HUS DATA TO BE REQUIRED

 SEATTLE, March 22 /PRNewswire/ -- IMRE Corporation (NASDAQ: IMRE) today announced that the U.S. Food and Drug Administration (FDA) is going to require additional data from a randomized clinical trial before any grant of approval to market the PROSORBA(R) column for the treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (C-TTP/HUS).
 The reason for the action is that the company is being requested to comply with new rules that were not in effect when the company conducted a multi-center study of the medical device for the treatment of C-TTP/HUS. The company has negotiated a protocol for the trial with the FDA and, as soon as an FDA-IDE is issued, the company is ready to commence the trial. The FDA agreed with the company to include classical TTP/HUS in the study. Classical TTP/HUS represents a market more than 10 times larger than the market for C-TTP/HUS.
 IMRE Corporation is a medical products company that is the leader in the field of immunoadsorption treatments. The company's first product, the PROSORBA column, has been approved by the Food and Drug Administration for the treatment of immune thrombocytopenic purpura, an immune-related bleeding disorder. The company is currently conducting clinical trials in rheumatoid arthritis, other autoimmune diseases, and certain cancers.
 -0- 3/22/93
 /CONTACT: Lois Yoshida of IMRE, 206-298-9400, or Ron Stabiner of The Wall Street Group, 212-888-4848, for IMRE/
 (IMRE)


CO: IMRE Corporation ST: Washington IN: MTC SU:

CK-MA -- NY009 -- 8092 03/22/93 09:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 22, 1993
Words:252
Previous Article:COPLEY PHARMACEUTICAL, INC. ANNOUNCES AGREEMENT FOR DEVELOPMENT, MANUFACTURING AND MARKETING OF OCULAR PRODUCTS
Next Article:ADVANCED INTERVENTIONAL SYSTEMS FILES PATENT INFRINGEMENT CLAIM
Topics:


Related Articles
IMRE ANNOUNCES PUBLICATION IN NEW ENGLAND JOURNAL OF MEDICINE
IMRE ANNOUNCES PMA EXPEDITED REVIEW
RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA COLUMN REPORTED BY IMRE CORPORATION
IMRE CORPORATION ANNOUNCES THIRD QUARTER RESULTS
IMRE CORPORATION ANNOUNCES YEAR-END RESULTS
IMRE CORPORATION ANNOUNCES FIRST QUARTER RESULTS
RHEUMATOID ARTHRITIS RESULTS FROM INDEPENDENT CLINICAL TRIAL OF PROSORBA COLUMN SHOW LONG-TERM EFFECTS
IMRE CORPORATION PRESENTS A METHOD TO TREAT BLEEDING DISORDERS
IMRE CORPORATION ANNOUNCES POSITIVE RHEUMATOID ARTHRITIS CLINICAL TRIAL RESULTS
IMRE CORPORATION RECEIVES CONDITIONAL APPROVAL TO BEGIN PIVOTAL RHEUMATOID ARTHRITIS CLINICAL TRIAL

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters